Another salient point from the study is that inhibition of ALDH2 combined with anti‐PD‐1 treatment could be used as a novel strategy to potentiate immune blockade therapy in CRC patients especially in the alcoholic population. The gene discussed is ALDH2; the disease is colorectal carcinoma.